NovoCure (BMV:NVCR N) - Cotización, noticias y análisis

Resumen de acción NVCR N

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally.

Acerca de la empresa

NVCR N fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 7.1%

Análisis de riesgos

Se prevé que los beneficios disminuyan un promedio de 5% al año durante los próximos 3 años

Acciones altamente ilíquidas

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de NovoCure Limited

Shinva Medical InstrumentLtd

SHSE:600587

CN¥10.9b

Shanghai MicroPort EP MedTech

SHSE:688351

CN¥12.4b

Beijing Wandong Medical TechnologyLtd

SHSE:600055

CN¥10.8b

MeHow Innovative

SZSE:301363

CN¥10.4b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for NovoCure
Historical stock prices
Current Share Price	US$275.39
52 Week High	US$2,140.47
52 Week Low	US$275.39
Beta	0.52
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-86.68%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	NVCR N	MX Medical Equipment	Mercado MX
7D	0%	0%	0%
1Y	n/a	0%	0%

Rentabilidad vs. Industria: Datos insuficientes para determinar los resultados de NVCR N en comparación con el sector MX Medical Equipment .

Rentabilidad vs. Mercado: Datos insuficientes para determinar el rendimiento de NVCR N frente al mercado MX.

Volatilidad de los precios

Is NVCR N's price volatile compared to industry and market?
NVCR N volatility
NVCR N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Precio estable de las acciones: NVCR N no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de NVCR N en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2000	1,320	Asaf Danziger	www.novocure.com

Resumen de fundamentos de NovoCure Limited

¿Cómo se comparan los beneficios e ingresos de NovoCure con su capitalización de mercado?
Estadísticas fundamentales de NVCR N
Capitalización bursátil	Mex$27.09b
Beneficios(TTM)	-Mex$3.35b
Ingresos (TTM)	Mex$8.56b

3.2x

Ratio precio-ventas (PS)

-8.1x

Ratio precio-beneficio (PE)

¿Está NVCR N sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NVCR N
Ingresos	US$503.98m
Coste de los ingresos	US$124.00m
Beneficio bruto	US$379.98m
Otros gastos	US$577.25m
Beneficios	-US$197.27m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-1.85
Margen bruto	75.40%
Margen de beneficio neto	-39.14%
Ratio deuda/patrimonio	144.3%

¿Cómo se ha desempeñado NVCR N a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción NVCR N

Recompensas

Análisis de riesgos

Competidores de NovoCure Limited

SHSE:600587

CN¥10.9b

SHSE:688351

CN¥12.4b

SHSE:600055

CN¥10.8b

SZSE:301363

CN¥10.4b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

Recent updates

NovoCure Limited announced that it expects to receive $400 million in funding

NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer

NovoCure Limited, Annual General Meeting, Jun 05, 2024

NovoCure Limited to Report Q1, 2024 Results on May 02, 2024

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Trident Trial in Newly Diagnosed Glioblastoma

NovoCure Limited Announces Executive Changes

Novocure Announces Portfolio Prioritization and Strategic Restructuring Plan Focused on Near-Term Growth Drivers and an Accelerated Path to Profitability

NovoCure Limited to Report Q3, 2023 Results on Oct 26, 2023

NovoCure Limited(NasdaqGS:NVCR) dropped from FTSE All-World Index (USD)

Novocure Announces the Lancet Oncology Publishes Primary Data from Phase 3 Lunar Clinical Trial in Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Levi & Korsinsky Notifies NovoCure Limited Investors of a Class Action Lawsuit and Upcoming Deadline

Chief Financial Officer recently sold Mex$589k worth of stock

Second quarter 2023 earnings released: US$0.54 loss per share (vs US$0.23 loss in 2Q 2022)

Novocure Announces Favorable Independent Data Monitoring Committee Recommendation to Continue Phase 3 Panova-3 Clinical Trial of Tumor Treating Fields Therapy in Pancreatic Cancer

NovoCure Limited to Report Q2, 2023 Results on Jul 27, 2023

Holzer & Holzer, LLC Files Lawsuit Against NovoCure Limited

Zai Lab and Novocure Announces Lunar Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies

Chief Operating Officer recently sold Mex$35m worth of stock

Chief Human Resources Officer recently sold Mex$383k worth of stock

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.56 loss in FY 2021)

Insufficient new directors

Novocure Announces Last Patient Enrolled in Pivotal PANOVA-3 Study of Tumor Treating Fields in Pancreatic Cancer

Novocure Announces Executive Changes

Zai Lab Limited and Novocure Announce Pivotal Lunar Study in Non-Small Cell Lung Cancer Met Primary Overall Survival Endpoint

Insufficient new directors

Insufficient new directors

Third quarter 2022 earnings released: US$0.25 loss per share (vs US$0.13 loss in 3Q 2021)

Insufficient new directors

Novocure Announces 11 Presentations on Tumor Treating Fields in Multiple Solid Tumor Types at the American Society for Radiation Oncology 2022 Annual Meeting

NovoCure Limited to Report Q3, 2022 Results on Oct 27, 2022

Insufficient new directors

Executive Chairman recently sold Mex$1.2m worth of stock

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.14 loss in 2Q 2021)

Insufficient new directors

NovoCure Limited to Report Q2, 2022 Results on Jul 28, 2022

Novocure Enrolls First Patient in KEYNOTE-B36, a Pilot Study of Tumor Treating Fields Together with KEYTRUDA® for Patients with First-Line Stage III Non-Small Cell Lung Cancer

Novocure and Zai Lab Announce EF-31 Phase 2 Pilot Study Evaluating Tumor Treating Fields Together with Standard-of-Care Chemotherapy Meets Primary Endpoint for First-Line Treatment of Gastric Cancer

Now 20% undervalued after recent price drop

Chief Medical Officer recently sold Mex$5.4m worth of stock

Insufficient new directors

NovoCure Limited, Annual General Meeting, Jun 08, 2022

NovoCure Limited to Report Q1, 2022 Results on Apr 28, 2022

General Counsel recently sold Mex$4.6m worth of stock

Insufficient new directors

Novocure Announces Resignation of Todd Longsworth as General Counsel

Insufficient new directors

President recently bought Mex$11m worth of stock

Insufficient new directors

NovoCure Limited Announces Last Patient Enrolled in Phase 3 Pivotal LUNAR Trial of Tumor Treating Fields in Non-small Cell Lung Cancer

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de NovoCure Limited

3.2x

-8.1x

Beneficios e Ingresos